Stockreport

Karolinska Development's portfolio company Modus Therapeutics initiates dosing in phase 2a study in patients with chronic kidney disease with anemia [Yahoo! Finance]

Nasdaq, Inc.  (NDAQ) 
Last nasdaq, inc. earnings: 4/22 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.nasdaq.com
PDF STOCKHOLM, SWEDEN December 10, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has dosed the fir [Read more]